肢端肥大症患者高凝状态的研究进展

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (10): 1426-1430.

肢端肥大症患者高凝状态的研究进展

马丽媛, 郭晓鹏, 幸兵^*

中国医学科学院北京协和医学院北京协和医院神经外科, 北京 100730

收稿日期:2019-09-26 修回日期:2019-12-30 出版日期:2020-10-05 发布日期:2020-09-29
通讯作者: ^* xingbingemail@aliyun.com
基金资助:
北京协和医学院研究生创新基金(2017-1002-2-18)

Research progress on hypercoagulable state in patients with acromegaly

MA Li-yuan, GUO Xiao-peng, XING Bing^*

Department of Neurosurgery, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2019-09-26 Revised:2019-12-30 Online:2020-10-05 Published:2020-09-29
Contact: ^* xingbingemail@aliyun.com

摘要/Abstract

摘要： 肢端肥大症患者因血中过量生长激素刺激可导致心血管、内分泌及代谢、骨骼及呼吸等全身多系统的合并症。除此之外,近年来大量证据表明肢端肥大症患者可合并凝血功能的改变,主要体现在凝血、抗凝、纤维蛋白溶解系统及血小板功能等多个方面,且呈现为高凝倾向。患者凝血功能检查可表现为明显升高的纤维蛋白原水平,明显降低蛋白C、蛋白S水平及增强的血小板功能;患者经过手术或药物治疗后,凝血功能指标可部分改善。

关键词: 肢端肥大症, 高凝状态, 纤维蛋白原, 蛋白C, 血小板

Abstract: Acromegaly is associated with systemic complications due to excess serum growth hormone, including cardiovascular diseases, endocrine and metabolic diseases, bone diseases and respiratory diseases. In addition, abnormalities of haemostatic function in patients with acromegaly have been described by several studies recently, including the alterations in coagulation, anticoagulation, fibrinolytic system and platelet function, presenting a potential of hyper-coagulation. Significantly elevated fibrinogen levels, reduced levels of protein C and protein S, and enhanced platelet activity were observed in patients with acromegaly. Some of these abnormalities are reversible after treatment like surgery or medication.

Key words: acromegaly, hypercoagulable state, fibrinogen, protein C, platelet

中图分类号:

R584.1

马丽媛, 郭晓鹏, 幸兵. 肢端肥大症患者高凝状态的研究进展[J]. 基础医学与临床, 2020, 40(10): 1426-1430.

MA Li-yuan, GUO Xiao-peng, XING Bing. Research progress on hypercoagulable state in patients with acromegaly[J]. Basic & Clinical Medicine, 2020, 40(10): 1426-1430.

参考文献

[1] Vilar L, Vilar CF, Lyra R, et al. Acromegaly: clinical features at diagnosis[J]. Pituitary, 2017,20: 22-32.
[2] Gadelha MR, Kasuki L, Lim DST, et al. Systemic complications of acromegaly and the impact of the current treatment landscape: an update[J]. Endocr Rev, 2019,40: 268-332.
[3] Dal J, Feldt-Rasmussen U, Andersen M, et al. Acrome-galy incidence, prevalence, complications and long-term prognosis: a nationwide cohort study[J]. Eur J Endocrinol, 2016,175: 181-190.
[4] Elarabi AM, Mosleh E, Alamlih LI, et al. Massive pulmonary embolism as the initial presentation of acromegaly: is acromegaly a hypercoagulable condition?[J]. Am J Case Rep, 2018,19: 1541-1545.
[5] Delaroudis SP, Efstathiadou ZA, Koukoulis GN, et al. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly[J]. Clin Endocrinol (Oxf), 2008,69: 279-284.
[6] Demirpence M, Yasar HY, Colak A, et al. Mean platelet volume and platelet function analysis in acromegalic patients before and after treatment[J]. Acta Endocrinol (Buchar), 2016,12: 401-406.
[7] Erem C, Nuhoglu I, Kocak M, et al. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI[J]. Endocrine, 2008,33: 270-276.
[8] Landin-Wilhelmsen K, Lundberg PA, Lappas G, et al. Insulin-like growth factor I levels in healthy adults[J]. Horm Res, 2004,62 Suppl 1: 8-16.
[9] Vilar L, Valenzuela A, Ribeiro-Oliveira A, et al. Multiple facets in the control of acromegaly[J]. Pituitary, 2014,17 Suppl 1: S11-17.
[10] Colak A, Yilmaz H, Temel Y, et al. Coagulation parameters and platelet function analysis in patients with acromegaly[J]. J Endocrinol Invest, 2016,39: 97-101.
[11] Amado A, Araujo F, Carvalho D. Cardiovascular risk factors in acromegaly: what's the impact of disease control?[J]. Exp Clin Endocrinol Diabetes, 2018,126: 505-512.
[12] Sartorio A, Cattaneo M, Bucciarelli P, et al. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly[J]. Exp Clin Endocrinol Diabetes, 2000,108: 486-492.
[13] Wildbrett J, Hanefeld M, Fucker K, et al. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I[J]. Exp Clin Endocrinol Diabetes, 1997,105: 331-335.
[14] Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: implications for new therapeutic strategies[J]. Res Pract Thromb Haemost, 2018,2: 188-198.
[15] Colao A, Grasso LFS, Di Somma C, et al. Acromegaly and Heart Failure[J]. Heart Fail Clin, 2019,15: 399-408.
[16] Mizera L, Elbaum M, Daroszewski J, et al. Cardiovascular complications of acromegaly[J]. Acta Endocrinologica-Bucharest, 2018,14: 365-374.
[17] Alakbarzade V, Taylor A, Scully M, et al. Utility of current thrombophilia screening in young patients with stroke and TIA[J]. Stroke Vasc Neurol, 2018,3: 231-236.
[18] Undas A, Natorska J. Improving fibrinolysis in venous thromboembolism: impact of fibrin structure[J]. Expert Rev Hematol, 2019,12: 597-607.
[19] Cwikiel J, Seljeflot I, Berge E, et al. Pro-coagulant activity during exercise testing in patients with coronary artery disease[J]. Thromb J, 2017,15: 3.
[20] Jung RG, Motazedian P, Ramirez FD, et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis[J]. Thromb J, 2018,16: 12.
[21] Erdogan M, Ozbek M, Akbal E, et al. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission[J]. Turk J Med Sci, 2019,49: 1381-1385.
[22] Dai H, Shi J, He Q, et al. Dose-response relationship between thrombin-activatable fibrinolysis Inhibitor (TAFI) and stroke: a Chinese case-control study[J]. Med Sci Monit, 2017,23: 4376-4381.
[23] Arpaci D, Kuzu F, Unal M, et al. Assessment of mean platelet volume and its effect on disease control in patients with acromegaly[J]. Clin Lab, 2016,62: 2167-2171.
[24] Ucler R, Aslan M, Atmaca M, et al. The effect of disease control on mean platelet volume and red blood cell distribution in patients with acromegaly[J]. Int J Clin Exp Med, 2015,8: 6060-6066.